The state awarded a $50 million contract to produce less costly treatments, but moves by major suppliers might undercut the initiative before any new product emerges.
https://siii-clinical.com/wp-content/uploads/2021/09/Untitled-1.png00https://siii-clinical.com/wp-content/uploads/2021/09/Untitled-1.png2023-03-24 16:17:102023-03-24 16:17:10California’s Plan for Cheaper Insulin Collides With Big Pharma’s Price Cuts
From research laboratories to clinical settings, SIII integrates the technologies, resources, and expertise our customers need to rise to the next opportunity. SIII is dedicated to exploring and researching the processes and scientific mechanisms underlying the world we live in.